<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01120119</url>
  </required_header>
  <id_info>
    <org_study_id>CLF-1 2005-000751-15</org_study_id>
    <nct_id>NCT01120119</nct_id>
  </id_info>
  <brief_title>Efficacy of Calcitriol in Recent Onset Type 1 Diabetes</brief_title>
  <acronym>IMDIABXIII</acronym>
  <official_title>Clinical Study to Evaluate the Efficacy of 1,25(OH)2D3 (Calcitriol) Versus Placebo in Recent Onset Type 1 Diabetes(IMDIAB XIII)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Campus Bio-Medico University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Campus Bio-Medico University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Reduction in vitamin D levels has been reported in subjects with recent onset type 1
      diabetes. Several studies suggest that vitamin D supplementation in early childhood decreases
      the risk of developing type 1 diabetes, therefore vitamin D deficiency might play a role in
      the disease pathogenesis. We investigated whether the supplementation of the active form of
      vitamin D (calcitriol) in subjects with recent-onset type 1 diabetes can protect residual
      beta cell function evaluated by C peptide and improve glycaemic control as evaluated by HbA1c
      and insulin requirement.

      Thirty-four subjects (age range 11-35 years, median 18 years) with recent-onset type 1
      diabetes (&lt;12 weeks duration) and high basal C-peptide &gt;0.25 nmol/l were randomized in a
      double-blind trial to calcitriol (the active form of vitamin D, 1.25-dihydroxyvitamin D3
      [1,25-(OH)2D3] ) at the dose of 0.25 ug/day or placebo, and followed up for 2 years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>C peptide</measure>
    <description>evaluation of baseline and stimulated C peptide</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycometabolic control</measure>
    <description>To measure insulin requirement and HbA1c</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Calcitriol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcitriol</intervention_name>
    <arm_group_label>Calcitriol</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. diagnosis of type 1 diabetes according to the American Diabetes Association (ADA)
             guidelines;

          2. age at presentation between 11 and 35 years;

          3. duration of clinical disease (since the beginning of insulin therapy) &lt;12 weeks;

          4. baseline C-peptide &gt;0.25 nmol/l;

          5. no medical contra-indications or any other major chronic disease;

          6. willingness and capability to participate in a regular follow-up.

        Exclusion Criteria:

          1. cardiovascular disease;

          2. renal disease;

          3. liver disease;

          4. neurological disorders;

          5. allergic diathesis;

          6. hyperparathyroidism;

          7. neoplasia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Campus Bio Medico</name>
      <address>
        <city>Rome</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bambino Gesù Children's Hospital</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic University,</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandro Pertini Hospital</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Sapienza</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Pitocco D, Crinò A, Di Stasio E, Manfrini S, Guglielmi C, Spera S, Anguissola GB, Visalli N, Suraci C, Matteoli MC, Patera IP, Cavallo MG, Bizzarri C, Pozzilli P; IMDIAB Group. The effects of calcitriol and nicotinamide on residual pancreatic beta-cell function in patients with recent-onset Type 1 diabetes (IMDIAB XI). Diabet Med. 2006 Aug;23(8):920-3.</citation>
    <PMID>16911633</PMID>
  </reference>
  <verification_date>March 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2010</study_first_submitted>
  <study_first_submitted_qc>May 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2010</study_first_posted>
  <last_update_submitted>May 7, 2010</last_update_submitted>
  <last_update_submitted_qc>May 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Paolo Pozzilli/Principal Investigator</name_title>
    <organization>University Campus Bio Medico</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

